Thermo Fisher Scientific Buys TREK Diagnostic Systems, Enhances Product Portfolio

Thermo Fisher Scientific Inc. (Waltham, MA, USA), a global instrumentation provider for scientific research and testing, acquired TREK Diagnostic Systems (Cleveland, OH, USA), an international microbiology solution provider, enhancing its product portfolio with automated and manual testing products.

Adding TREK's automated platforms to its product line enables Thermo Fisher to complement its existing manual blood culture systems and offer a comprehensive choice of sepsis and tuberculosis tests and culture media. TREK's manual platform expands Thermo Fisher's range of manual susceptibility testing and identification products.

“This acquisition is an important step in our strategy to bring a greater choice of workflow solutions to microbiologists worldwide,” said Andrew Carr, president, microbiology, Thermo Fisher Scientific. “TREK is an ideal complement to our existing capabilities, allowing us to offer comprehensive solutions to aid in the diagnosis of sepsis. We can now provide easier access to technology used in the setting of global standards in antimicrobial susceptibility testing, for targeted antibiotic therapy and promotion of good antibiotic stewardship. And we will now offer a fully automated alternative for mycobacterial detection and resistance, crucial to the diagnosis of tuberculosis. Additionally, TREK has a significant product development pipeline that will be enhanced by the expertise and resources of Thermo Fisher Scientific.”

Related Links:
Thermo Fisher Scientific
TREK Diagnostic Systems